QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 allarity-therapeutics-implements-1-for-30-reverse-stock-split-to-regain-nasdaq-listing-compliance

Shareholders Approved The Split At September 3, 2024 Annual Meeting, And Split Took Effect On September 11, 2024

 allarity-therapeutics-files-for-offering-of-up-to-185m-shares-by-the-selling-stockholders

- SEC Filing

 allarity-therapeutics-13g-filing-shows-streeterville-capital-llc-reported-a-147-stake-in-the-co-as-of-august-19-2024

- SEC Filing

 allarity-therapeutics-hit-by-sec-notice-related-disclosures-of-once-lead-cancer-program

Allarity Therapeutics receives a Wells Notice from the SEC regarding disclosures about their FDA meetings for the New Drug Appl...

 allarity-received-a-wells-notice-from-sec-relating-to-its-disclosures-regarding-meetings-with-the-fda-regarding-nda-for-dovitinib-or-dovitinib-drp-which-was-submitted-in-2021-allaritys-three-former-officers-have-received-the-notice

Current Cash Balance of $20 million Expected to Provide Runway Into 2026 Allarity to Pause Use of ATM Cap Table Successfull...

 sec-issues-wells-notice-to-allarity-therapeutics-and-former-officers-over-2021-fda-nda-submission

On July 19, 2024, Allarity Therapeutics, Inc. (the “Company”) received a “Wells Notice” from the Staff of the U.S. Securities a...

 allarity-granted-hearing-before-nasdaq-panel-to-present-plan-of-regaining-compliance

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutica...

 allarity-therapeutics-dual-parptankyrase-inhibitor-stenoparib-to-show-extended-clinical-benefit-in-advanced-ovarian-cancer

Multiple patients have now exceeded 30 weeks on treatment Boston (June 25, 2024)—Allarity Therapeutics, Inc. ("Allarity"...

 why-allarity-therapeutics-allr-stock-is-getting-hammered

Allarity Therapeutics shares are trading lower by 27.6% during Monday's session. The company announced that it received a n...

 reported-earlier-allarity-therapeutics-faces-nasdaq-delisting-for-stock-price-below-1

On June 18, 2024, Allarity Therapeutics, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Staff (t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION